Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and ...

medicines for diabetes and cardiovascular diseases; and established prescription products. Receive News & Ratings for Sanofi ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Researchers are exploring how small airway abnormalities in younger smokers could help identify who is at risk of developing COPD and establish how the chronic lung disease progresses.

Sanofi, who will lead the global diabetes and cardiovascular care business unit in the company's new organisational structure. "The life sciences team at Google can help us improve the patient ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

It can also help to reduce the risk of heart attack and stroke in adults with type 2 diabetes ... It is no longer available ...

Finally, Mohammed Charki joined Sanofi as a project manager on a telemonitoring and decision support program for Type 2 Diabetes Mellitus patients and HCPs and then as cardiovascular Portfolio ...

Medical experts have decried the skyrocketing cost and unavailability of diabetes medications in the country. This was even ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on AstraZeneca (AZN – Research Report), with ...

AstraZeneca’s AZN third-quarter 2024 core earnings of $1.04 per American depositary share (ADS) beat the Zacks Consensus ...